Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04040231 · ClinicalTrials.gov registry record · Phase 1
Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT04040231: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT04040231 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04040231, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to test whether it is safe to give Galinpepimut-S and Nivolumab together in patients with mesothelioma.
Interventions
- DRUG Nivolumab
- BIOLOGICAL Sargramostim
- BIOLOGICAL Galinpepimut-S
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-07-24 |
| Est. Completion | 2024-11-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04040231
The ClinicalTrials.gov registry entry for NCT04040231 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT04040231 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04040231 about?
NCT04040231 is a clinical study titled "Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma". The purpose of this study is to test whether it is safe to give Galinpepimut-S and Nivolumab together in patients with mesothelioma.
What is the current status of trial NCT04040231?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2019-07-24. Estimated completion is 2024-11-14.
What interventions are being tested in trial NCT04040231?
The interventions under investigation include: Nivolumab (DRUG), Sargramostim (BIOLOGICAL), Galinpepimut-S (BIOLOGICAL).
Who is sponsoring clinical trial NCT04040231?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.